A NEW drug developed as part of a study undertaken by the Centenary Institute and UNSW Sydney is being claimed as a potential way to target high rates of obesity in Australia.
The medication targets a specific Ceramide Synthase enzyme in metabolic disease, with is linked to insulin resistance.
A paper on the research has been published in the Nature Communications journal.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Aug 18
